NewsFix
Would you like to react to this message? Create an account in a few clicks or log in to continue.

Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market

2 posters

Go down

Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market Empty Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market

Post by Guest Sat Dec 09, 2017 3:06 pm

After decades without effective medications to prevent migraines, sufferers may have new options coming to the market soon. Two new drugs targeting the same pathway in the brain may cut down on the number and the length of migraines people suffer, separate studies published Wednesday in the New England Journal of Medicine have shown.

Migraines are not just headaches. There is a headache involved, certainly, but migraine pain is far more severe. People may also be extremely sensitive to light and sound while a migraine is happening and even vomit. Some people can predict when a migraine will next strike because of warning signs they feel, called auras. According to MedlinePlus, up to 12 percent of Americans have migraines.
Currently, the most effective drugs used to treat migraines are primarily designed to be used once a migraine starts. People may also adjust their lives to avoid things that trigger the migraines or use drugs not intended to specifically treat migraines.

People with migraines are thought to have too much of a protein called calcitonin gene-related peptide (CGRP) in their brains; both drugs work to try and reduce the effect of CGRP on neurons in different ways. One,fremanezumab, binds to CGRP directly so it can’t bind to brain cells and have an effect. The other, erenumab, blocks the receptor on brain cells to which CGRP binds.

“These drugs may find a specific role in the treatment of patients who have migraines that are refractory to treatment or who are severely disabled by headaches,” wrote from the Cincinnati Children’s Hospital Medical Center in an editorial that accompanied the studies.

One of the authors of the erenumab study was more direct about the drug’s potential impact in an interview with the BBC. "It's a huge deal because it offers an advance in understanding the disorder and a designer migraine treatment,” Dr. Peter Goadsby at King’s College Hospital said. "These patients will have parts of their life back and society will have these people back functioning."

In addition to acting differently, the two drugs were also tested for different types of migraines: episodic vs. chronic. People with chronic migraines have more episodes over a longer period of time than those with episodic migraines. One drug, erenumab, was used specifically to prevent episodic migraines.

The study followed nearly 1,000 people over six months and tested two different dosages of the drug. When patients began the trial, most were suffering from migraines at least eight days each month.  About half of the patients taking the drug had at least three to four fewer migraine days per month than they were having before, regardless of the dose. 

Similar results were seen for fremanezumab, which was tested for chronic migraine patients. On average, patients who took the drug—regardless of the dosing schedule, which was either once every three months or once every month—had about four fewer days with headaches than those who were on a placebo drug. About 40 percent of the patients on the drug had half as many headache days on the drug. At the beginning of the trial, the average person was affected for nearly half of the month.
Each of the studies were funded by the companies developing the drugs; Amgen and Novartis are responsible for erenumab, while Teva is working on fremanezumab.

According to Amgen’s pipeline, which lists all the drugs the company is currently developing, erenumab will be called Aimovig when and if it reaches the U.S. market. (Amgen is developing the drug with Novartis.) The FDA may approve the drug for one group of migraine patients—those who have at least four migraine days per month—in May. 

Teva is the pharmaceutical company behind second drug, fremanezuma, intended to treat chronic migraines. The company just submitted an application to the FDA for the drug’s approval in October.




https://www.goodnewsnetwork.org/two-breakthrough-drugs-treat-migraines-may-soon-hit-market/

Guest
Guest


Back to top Go down

Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market Empty Re: Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market

Post by Raggamuffin Sat Dec 09, 2017 3:55 pm

You can also have the aura without a headache. I know a few people who do, including myself. I wouldn't bother with a drug for it though - it passes on its own. For those who get headache and feel awful, I hope something works for them.
Raggamuffin
Raggamuffin
Forum Detective ????‍♀️

Posts : 33746
Join date : 2014-02-10

Back to top Go down

Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market Empty Re: Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market

Post by Cass Sat Dec 09, 2017 4:16 pm

Raggamuffin wrote:You can also have the aura without a headache. I know a few people who do, including myself. I wouldn't bother with a drug for it though - it passes on its own. For those who get headache and feel awful, I hope something works for them.

My eyesight gets fuzzy, I get a bad taste in my mouth and then I throw up. Some can last 1-2 hours, others for days. There is no reason (wine, chocolate, food additives etc...) and they are random. If it goes beyond 4 hours of lying in the dark I take the big pills and try and sleep through it, but as you know, it hurts to breath.

I hope this breakthrough works. I know people who are much worse than I am.
Cass
Cass
the Nerd Queen of Nerds, the Lover of Books who Cooks

Posts : 6617
Join date : 2014-01-19
Age : 56

Back to top Go down

Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market Empty Re: Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market

Post by Sponsored content


Sponsored content


Back to top Go down

Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum